Skip to main content

Table 2 Adjusted mean functional outcome scores by treatment type, SA-PCCOC registry (2010–2019)

From: Patient-reported functional outcome measures and treatment choice for prostate cancer

 

Rx

Sexual

function

Urinary

incontinence

Urinary

obstruction

Bowel

function

Mean

95% CI

Mean

95% CI

Mean

95% CI

Mean

95% CI

Baseline scores‡

RP

56.3

54.1, 58.4

89.9

88.8, 91.0

85.9

84.8, 87.0

93.5

92.8, 94.3

EBRT

45.8

41.7, 49.9

89.5

87.3, 91.6

82.2

79.9, 84.4

90.6

89.0, 92.2

BT

61.4

54.6, 68.2

90.0

86.8, 93.2

83.1

79.7, 86.4

91.0

88.5, 93.5

AS

52.8

48.4, 57.2

88.8

86.5, 91.1

84.1

81.7, 86.4

92.3

90.6, 94.1

12-month scores¥

RP

28.5

26.5, 30.6

74.4

72.5, 76.3

91.8

90.7, 92.8

92.7

91.7, 93.6

EBRT

35.0

30.0, 39.9

88.0

84.0, 91.9

84.5

81.2, 87.8

84.7

80.5, 89.0

BT

45.9

38.3, 53.6

85.0

78.4, 91.6

84.8

80.2, 89.4

90.8

87.6, 94.1

AS

35.4

28.7, 42.2

85.0

80.8, 89.2

91.6

88.7, 94.4

90.6

88.4, 92.8

Change scores‡

RP

-28.9

-31.7, -26.2

-15.6

-17.7, -13.5

5.6

4.2, 6.9

-0.8

-1.8, 0.1

EBRT

-16.5

-24.2, -8.8

-2.2

-6.5, 2.1

2.0

-2.7, 6.7

-6.3

-11.3, -1.2

BT

-17.8

-27.1, -8.6

-5.4

-11.8, 1.1

1.7

-4.5, 7.8

-1.1

-4.9, 2.7

AS

-22.1

-30.0, -14.3

-5.9

-10.2, -1.7

3.9

0.7, 7.0

-4.4

-6.6, -2.1

Mean difference¥¥

RP

reference

       

EBRT

6.4

0.9, 12.0*

13.6

9.0, 18.2***

-7.2

–10.7, − 3.8***

–7.9

–12.4, − 3.5***

BT

17.4

9.4, 25.5***

10.6

3.9, 17.3***

-6.9

–11.7, − 2.2***

–1.8

–5.1, 1.5

AS

6.9

–0.5, 14.3

10.6

5.9, 15.3***

-0.2

–3.5, 3.1

–2.1

–4.4, 0.2

  1. Rx, treatment; RP, radical prostatectomy; EBRT, external beam radiation therapy; BT, brachytherapy; AS, active surveillance; CI, confidence interval
  2. ‡Adjusted for age, SEIFA score, PSA level, risk category and primary symptoms
  3. ¥Adjusted for baseline score of the respective function, age, SEIFA score, PSA level, risk category and primary symptoms
  4. ¥¥The adjusted mean difference in the 12 months functional scores between EBRT, brachytherapy, active surveillance vs. RP from linear regression models
  5. All analyses were with the weighted sample
  6. *p < 0.05, **p < 0.01, ***p < 0.001